Policy & Market
Sep 25, 2026 · 1 min read · 36,244 views
Post-Hoc Live: The China Biotech Debate goes to Washington
N
Noah Patel
Editorial · Sep 25, 2026
takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and secrecy
← Previous
Eli Lilly invests in startup Abridge for clinical trial recruitment
Next →
Updated: Ultragenyx's new gene therapy will cost $3.95M
